JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection

  • 0Henan Institute of Medical and Pharmaceutical Sciences & Henan Key Medical Laboratory of Tumor Molecular Biomarkers, Zhengzhou University, Zhengzhou, China.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology +

|

December 19, 2024

|

December 19, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Autoantibodies targeting Ferredoxin 1 (FDX1) show promise as biomarkers for detecting non-small cell lung cancer (NSCLC). Elevated anti-FDX1 autoantibody levels were observed in NSCLC patients, suggesting potential for early cancer diagnosis.

Area Of Science

  • Oncology
  • Immunology
  • Biomarker Discovery

Background

  • Autoantibodies are potential biomarkers for early cancer detection.
  • Ferredoxin 1 (FDX1) influences cuproptosis and lung cancer prognosis.
  • Investigating anti-FDX1 autoantibodies for non-small cell lung cancer (NSCLC) detection.

Purpose Of The Study

  • To evaluate the anti-FDX1 autoantibody as a novel biomarker for NSCLC detection.
  • To assess the diagnostic accuracy of anti-FDX1 autoantibodies in distinguishing NSCLC from benign conditions and healthy controls.

Main Methods

  • Analyzed 1,155 plasma samples using ELISA, Western blotting, and immunofluorescence.
  • Included 414 NSCLC patients, 327 benign pulmonary nodule (BPN) patients, and 414 normal controls (NC).
  • Verified and validated anti-FDX1 autoantibody expression levels.

Main Results

  • Significantly higher plasma anti-FDX1 autoantibody levels in NSCLC patients compared to BPN and NC groups.
  • Confirmed ELISA findings with Western blotting and immunofluorescence.
  • Achieved an AUC of 0.806 for distinguishing NSCLC from NC and 0.627 for NSCLC from BPN.

Conclusions

  • The anti-FDX1 autoantibody demonstrates potential as a novel biomarker for NSCLC detection.
  • Anti-FDX1 autoantibodies may aid in facilitating NSCLC diagnosis.